Hemostemix Inc

Common Stock International Reporting
Verified Company Profile 6/29/2016
Contact Info
  • Suite 730
  • 1015 - 4th Street SW
  • Calgary, ALB T2R 1J4
  • Canada

Business Description

Financial Reporting/Disclosure
Reporting Status International Reporting: Toronto Stock Exchange
Audited Financials Audited
Latest Report Jun 30, 2016 Interim Financial Report
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 8000 - Services-Health Services
Incorporated In: Canada
Year of Inc. 2014
Employees 12 a/o Oct 12, 2015
Company Officers/Contacts
Dr. Elmar Burchardt CEO
Angus Jenkins COO
David Berman CFO, IR
Dr. Ina Sarel VP, R&D
Dr. Hardean E. Achneck Other
Company Directors
Angus Jenkins Chairman
Lee Buckler
Robert L. Buckler
Dr. Elmar Burchardt
Victor H. Redekop
Service Providers
Accounting/Auditing Firm
2701 Evans Avenue
8th Floor
Toronto, ONT, M9C 1A3

Legal Counsel
Heighenton Law Firm
1015 - 4 St SW, Suite 730
Calgary, ALB, T2R 1J4

Investor Relations Firm
Not Available
HMTXF Security Details
Share Structure
Market Value1 $27,496,110 a/o Oct 24, 2016
Authorized Shares Unlimited a/o Oct 05, 2015
Outstanding Shares 67,858,119 a/o Sep 20, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 65,802,119 a/o Oct 05, 2015
Par Value Not Available
Shareholders of Record Not Available
Non US Stock Exchange Listing
HEM - Toronto Stock Exchange - Qualified
Short Selling Data
Short Interest 0 (-100%)
Mar 15, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security